Copper in Alzheimer’s disease: too much or too little?

References

• Brewer GJ. The risks of free copper in the body and the development of useful anticopper drugs. Curr. Opin. Clin. Nutr. Metab. Care11(6), 727–732 (2008).
   PubMed Web of Science ®Google Scholar
• Brewer GJ. Copper in medicine. Curr. Opin. Chem. Biol.7(2), 207–212 (2003).
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Askari FK. Wilson’s disease: clinical management and therapy. J. Hepatol.42(Suppl. 1), S13–S21 (2005).
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Hedera P, Kluin KJ et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol.60(3), 379–385 (2003).
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Askari F, Lorincz MT et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch. Neurol.63(4), 521–527 (2006).
   PubMed Web of Science ®Google Scholar
• Brewer GJ. Zinc acetate for the treatment of Wilson’s disease. Expert Opin. Pharmacother.2(9), 1473–1477 (2001).
   PubMedGoogle Scholar
• Cheah DM, Deal YJ, Wright PF et al. Heterozygous tx mice have an increased sensitivity to copper loading: implications for Wilson’s disease carriers. Biometals20(5), 751–757 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar N, Low PA. Myeloneuropathy and anemia due to copper malabsorption. J. Neurol.251(6), 747–749 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar N, Crum B, Petersen RC, Vernino SA, Ahlskog JE. Copper deficiency myelopathy. Arch. Neurol.61(5), 762–766 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology63(1), 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin. Proc.81(10), 1371–1384 (2006).
   PubMed Web of Science ®Google Scholar
• Gambling L, Andersen HS, McArdle HJ. Iron and copper, and their interactions during development. Biochem. Soc. Trans.36(Pt 6), 1258–1261 (2008).
   PubMed Web of Science ®Google Scholar
• Maynard CJ, Cappai R, Volitakis I et al. Overexpression of Alzheimer’s disease amyloid-β opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem.277(47), 44670–44676 (2002).
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297(5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Phinney AL, Drisaldi B, Schmidt SD et al.In vivo reduction of amyloid-β by a mutant copper transporter. Proc. Natl Acad. Sci. USA100(24), 14193–14198 (2003).
   PubMed Web of Science ®Google Scholar
• Bayer TA, Schafer S, Simons A et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice. Proc. Natl Acad. Sci. USA100(24), 14187–14192 (2003).
   PubMed Web of Science ®Google Scholar
• Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J. Copper depletion down-regulates expression of the Alzheimer’s disease amyloid-β precursor protein gene. J. Biol. Chem.279(19), 20378–20386 (2004).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl Acad. Sci. USA100(19), 11065–11069 (2003).
   PubMed Web of Science ®Google Scholar
• Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer’s Aβ peptides. J. Biol. Inorg. Chem.9(8), 954–960 (2004).
   PubMed Web of Science ®Google Scholar
• Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron30(3), 665–676 (2001).
   PubMed Web of Science ®Google Scholar
• Opazo C, Huang X, Cherny RA et al. Metalloenzyme-like activity of Alzheimer’s disease β-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J. Biol. Chem.277(43), 40302–40308 (2002).
   PubMed Web of Science ®Google Scholar
• Puglielli L, Friedlich AL, Setchell KD et al. Alzheimer disease β-amyloid activity mimics cholesterol oxidase. J. Clin. Invest.115(9), 2556–2563 (2005).
   PubMed Web of Science ®Google Scholar
• Crouch PJ, Blake R, Duce JA et al. Copper-dependent inhibition of human cytochrome C oxidase by a dimeric conformer of amyloid-β1–42. J. Neurosci.25(3), 672–679 (2005).
   PubMed Web of Science ®Google Scholar
• House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therapy in Alzheimer’s disease. J. Alzheimers Dis.6(3), 291–301 (2004).
   PubMed Web of Science ®Google Scholar
• Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of β-sheets of Aβ-42 in senile plaque cores in Alzheimer’s disease. J. Alzheimers Dis.10(2–3), 173–177 (2006).
   PubMed Web of Science ®Google Scholar
• Khan A, Dobson JP, Exley C. Redox cycling of iron by Aβ42. Free Radic. Biol. Med.40, 557–569 (2006).
   PubMed Web of Science ®Google Scholar
• Schuessel K, Schafer S, Bayer TA et al. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis.18(1), 89–99 (2005).
   PubMed Web of Science ®Google Scholar
• Treiber C, Simons A, Strauss M et al. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer’s disease. J. Biol. Chem.279(50), 51958–51964 (2004).
   PubMed Web of Science ®Google Scholar
• White AR, Du T, Laughton KM et al. Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem.281(26), 17670–17680 (2006).
   PubMed Web of Science ®Google Scholar
• Cater MA, McInnes KT, Li QX et al. Intracellular copper deficiency increases amyloid-β secretion by diverse mechanisms. Biochem. J.412(1), 141–152 (2008).
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J. Inorg. Biochem.98(12), 2160–2167 (2004).
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick RD, Grover DK et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin. Cancer Res.6(1), 1–10 (2000).
   PubMed Web of Science ®Google Scholar
• Wadsworth TL, Bishop JA, Domes CM, Ralle M, Brewer G, Quinn JF. Copper complexing with tetrathiomolybdate in a murine model of Alzheimer’s disease. Society for Neuroscience Abstracts (2007).
   Google Scholar
• Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J. Neurol. Sci.143(1–2), 137–142 (1996).
   PubMed Web of Science ®Google Scholar
• Loeffler DA, LeWitt PA, Juneau PL et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res.738(2), 265–274 (1996).
   PubMed Web of Science ®Google Scholar
• Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci.158(1), 47–52 (1998).
   PubMed Web of Science ®Google Scholar
• Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and x-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer's disease. J. Struct. Biol.155(1), 30–37 (2006).
   PubMed Web of Science ®Google Scholar
• Connor JR, Tucker P, Johnson M, Snyder B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer’s disease. Neurosci. Lett.159(1–2), 88–90 (1993).
   PubMed Web of Science ®Google Scholar
• Squitti R, Barbati G, Rossi L et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau. Neurology67(1), 76–82 (2006).
   PubMed Web of Science ®Google Scholar
• Capo CR, Arciello M, Squitti R et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer’s disease patients. Biometals21(3), 367–372 (2008).
   PubMed Web of Science ®Google Scholar
• Molina JA, Jimenez-Jimenez FJ, Aguilar MV et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer’s disease. J. Neural Transm.105(4–5), 479–488 (1998).
   PubMed Web of Science ®Google Scholar
• Squitti R, Lupoi D, Pasqualetti P et al. Elevation of serum copper levels in Alzheimer’s disease. Neurology59(8), 1153–1161 (2002).
   PubMed Web of Science ®Google Scholar
• Squitti R, Pasqualetti P, Cassetta E et al. Elevation of serum copper levels discriminates Alzheimer’s disease from vascular dementia. Neurology60(12), 2013–2014 (2003).
   PubMed Web of Science ®Google Scholar
• Squitti R, Pasqualetti P, Dal Forno G et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology64(6), 1040–1046 (2005).
   PubMed Web of Science ®Google Scholar
• Squitti R, Ventriglia M, Barbati G et al. ‘Free’ copper in serum of Alzheimer’s disease patients correlates with markers of liver function. J. Neural Transm.114(12), 1589–1594 (2007).
   PubMed Web of Science ®Google Scholar
• Pajonk FG, Kessler H, Supprian T et al. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer’s disease. J. Alzheimers Dis.8(1), 23–27 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler H, Pajonk FG, Meisser P et al. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer‘s disease. J. Neural Transm.113(11), 1763–1769 (2006).
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Mackinnon A et al. Metal–protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol.60(12), 1685–1691 (2003).
   PubMed Web of Science ®Google Scholar
• Tabira T. Clioquinol’s return: cautions from Japan. Science292(5525), 2251–2252 (2001).
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol.7(9), 779–786 (2008).
   PubMed Web of Science ®Google Scholar
• Kessler H, Bayer TA, Bach D et al. Intake of copper has no effect on cognition in patients with mild Alzheimer’s disease: a pilot Phase 2 clinical trial. J. Neural Transm.115(8), 1181–1187 (2008).
   PubMed Web of Science ®Google Scholar
• Kessler H, Pajonk FG, Bach D et al. Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot Phase II clinical trial. J. Neural Transm.115(12), 1651–1659 (2008).
   PubMed Web of Science ®Google Scholar
• Squitti R, Rossini PM, Cassetta E et al.D-penicillamine reduces serum oxidative stress in Alzheimer’s disease patients. Eur. J. Clin. Invest.32(1), 51–59 (2002)
   PubMed Web of Science ®Google Scholar
• González C, Martín T, Cacho J et al. Serum zinc, copper, insulin and lipids in Alzheimer’s disease epsilon 4 apolipoprotein E allele carriers. Eur. J. Clin. Invest.29(7), 637–642 (1999).
   PubMed Web of Science ®Google Scholar